People: Ibio Inc (IBIO.A)

Summary

Name	Age	Since	Current Position
Robert Kay	72	2009	Executive Chairman of the Board, Chief Executive Officer
Robert Erwin	58	2008	President
Scott Kain	35	2013	Chief Financial Officer
Andrea Corcoran	45	2012	Senior Vice President - Finance and Strategy
Terence Ryan	57	2012	Chief Scientific Officer
Seymour Flug	73	2012	Director
Glenn Chang	64	2008	Independent Director
Arthur Elliott	76	2010	Independent Director
James Hill	66	2008	Independent Director
John McKey	69	2008	Independent Director
Philip Russell	80	2010	Independent Director

» Insider Trading

Biographies

Name	Description
Robert Kay	Mr. Robert B. Kay serves as Executive Chairman of the Board, Chief Executive Officer of iBio Inc. He became a Director since the company became a publicly traded company in August 2008. Mr. Kay was a founder and senior partner of the New York law firm of Kay Collyer & Boose LLP, with a particular focus on mergers and acquisitions and joint ventures. He is also a principal and Chairman of Seaway Biltmore, Inc., a hotel ownership and management company. Mr. Kay received his B.A. from Cornell University’s College of Arts & Sciences and his J.D. from New York University Law School.
Robert Erwin	Mr. Robert L. Erwin serves as President of iBio Inc., since August 2008. Mr. Erwin led Large Scale Biology Corporation from its founding in 1988 through 2003, including an initial public offering in 2000, and continued as non-executive Chairman until 2006. He served as Chairman of Icon Genetics AG from 1999 until its acquisition by a subsidiary of Bayer AG in 2006. Mr. Erwin recently served as Managing Director of Bio-Strategic Directors LLC, providing consulting services to the life sciences industry. He is currently Chairman of Novici Biotech, a private biotechnology company and a Director of Resolve Therapeutics. Mr. Erwin’s non-profit work focuses on applying scientific advances to clinical medicine, especially in the field of oncology. He is co-founder, President and Director of the Marti Nelson Cancer Foundation, Oncology. Mr. Erwin received his BS degree with Honors in Zoology and an MS degree in Genetics from Louisiana State University.
Scott Kain	Mr. Scott Kain is appointed as the Chief Financial Officer of iBio, Inc. Mr. Kain is a Certified Public Accountant in the Commonwealth of Pennsylvania who most recently served as the Associate Director of Financial Reporting at Enzon Pharmaceuticals, Inc., a NASDAQ listed company, where he was employed since 2011. In this capacity, Mr. Kain had principal responsibility for the preparation and filing of SEC periodic reports, technical accounting matters and oversight of Enzon’s internal controls over financial reporting in accordance with SOX 404 requirements. Additionally, while at Enzon, Mr. Kain also led the Treasury and Financial Planning and Analysis functions entailing oversight of the corporate cash management program and development of corporate operating and capital budgets. Prior to joining Enzon, Mr. Kain was employed from 2005 to 2010 at Sopherion Therapeutics LLC, a pre-IPO venture-backed biotechnology company, where he held financial and global operational management roles beginning as Manager of Financial Reporting and ending as Director of Clinical Supply Chain. Mr. Kain began his career in public accounting in the assurance practice of Ernst & Young LLP. Mr. Kain earned a B.A. in Economics magna cum laude from Bucknell University and an M.S. in Accounting from the University of Virginia. He is a member of the American Institute of Certified Public Accountants and the Pennsylvania Institute of Certified Public Accountants.
Andrea Corcoran	Ms. Andrea J. Corcoran has been appointed as the Senior Vice President - Finance and Strategy of iBio Inc. Ms. Corcoran joins iBio following roles with increasing responsibility for corporate, financial and business development strategy formation and operations at Idenix Pharmaceuticals, Inc., and Tolerx, Inc., each biopharmaceutical companies engaged in the discovery and development new and innovative pharmaceutical products.
Terence Ryan	Mr. Terence Ryan, Ph.D., serves as Chief Scientific Officer of iBio Inc., since March 2012. He previously served as Assistant Vice President, Systems Biology at Wyeth Pharmaceuticals (later Pfizer, Inc.) from 2007-2010, and Director of Integrative Biology at GlaxoSmithKline from 2003-2007. He has also been Director, Cell Biology at Celera Genomics (2000-2003), and Associate Director of Cell Technologies and Protein Sciences at Regeneron Pharmaceuticals. He received his A.B. In Biology from Princeton University, and his M.S. and Ph.D. in Microbiology from Rutgers University. He also was a post-doctoral fellow in Molecular Virology at the University of Wisconsin.
Seymour Flug	Mr. Seymour Flug has been appointed as Director of iBio Inc. Mr. Flug most recently was the former chairman, president and CEO of Diner’s Club International and a managing director at Citibank. Previously he served as a Senior Vice President at Hess Oil Company.
Glenn Chang	Mr. Glenn J. Chang serves as an Independent Director of iBio Inc., since August 2008. Since 1999 he has been Director, Executive Vice President and Chief Financial Officer of the First American International Bank, Brooklyn, N.Y. Prior to the founding of the Bank he spent almost 20 years at Citibank as Vice President. Mr. Chang is a Certified Public Accountant.
Arthur Elliott	Dr. Arthur Y. Elliott, Ph.D., serves as an Independent Director of iBio, Inc. Dr. Elliott spent 16 years with Merck & Co., serving ultimately as Executive Director of Biological Operations, Merck Manufacturing Division, responsible for the bulk manufacture, testing, release and registration of all biological products sold. Dr. Elliott has served with the United States Department of Health and Human Services in the Avian Influenza Pandemic Preparedness Program in Washington, D.C. as Senior Program Manager for the Antigen Sparing Project since 2006. The program involves the cooperation of three pharmaceutical companies and four government groups (NIH, CDC, FDA, and HHS). While at Merck, he worked closely with both Merck Research Laboratories and the Merck Vaccine Division to forecast the timely transfer of technology for new and improved products from the research laboratories through the manufacturing area and into the marketing division for sales introductions. He has served as a biological consultant to the World Health Organization, National Institutes of Health, and The Bill & Melinda Gates Foundation. Dr. Elliott holds a Ph.D. in Virology from Purdue University, and an M.S. in Microbiology and a B.A. in Biology from North Texas State University. He serves as a member of the American Association for Advancement of Science, American Society for Microbiology, and American Tissue Culture Association.
James Hill	General (Retired) James T. Hill serves as an Independent Director of iBio Inc., since August 2008. At the time of his retirement from active duty, General Hill was the Commander of the 4-Star United States Southern Command, reporting directly to the President and Secretary of Defense. As such he led all U.S. military forces and operations in Central America, South America and the Caribbean, worked directly with U.S. Ambassadors, foreign heads of state, key Washington decision-makers, foreign senior military and civilian leaders, developing and executing United States policy. His responsibilities included management, development and execution of plans and policy within the organization including programming, communications, manpower, operations, logistics and intelligence.
John McKey	Mr. John D. McKey, Jr., serves as an Independent Director of iBio Inc., since August 2008. Since 2003, Mr. McKey has served as of counsel at McCarthy, Summers, Bobko, Wood, Sawyer & Perry, P.A. in Stuart, Florida, and previously was a partner from 1987 through 2003. From 1977 to 1987 Mr. McKey was a partner at Gunster Yoakley in Palm Beach, Florida. Mr. McKey received his B.B.A at the University of Georgia and his J.D. from the University of Florida College of Law.
Philip Russell	Dr. Philip K. Russell, M.D., serves as an Independent Director of iBio Inc. He served in the U.S. Army Medical Corps from 1959 to 1990, pursuing a career in infectious disease and tropical medicine research. Following his military service, he joined the faculty of Johns Hopkins University’s School of Hygiene and Public Health and worked closely with the World Health Organization as special advisor to the Children’s Vaccine Initiative. He was founding board member of the International AIDS Vaccine Initiative, and is an advisor to the Bill and Melinda Gates Foundation. He has served on numerous advisory boards of national and international agencies, including the Centers for Disease Control, National Institutes of Health, and the Institute of Medicine. He is the past Chairman of the Albert B. Sabin Vaccine Institute.

Basic Compensation

Name	Fiscal Year Total
Robert Kay	808,888
Robert Erwin	746,388
Scott Kain	--
Andrea Corcoran	--
Terence Ryan	--
Seymour Flug	--
Glenn Chang	--
Arthur Elliott	--
James Hill	--
John McKey	--
Philip Russell	--

As Of 29 Jun 2012

Options Compensation

Name	Options	Value
Robert Kay	0	0
Robert Erwin	0	0
Scott Kain	0	0
Andrea Corcoran	0	0
Terence Ryan	0	0
Seymour Flug	0	0
Glenn Chang	0	0
Arthur Elliott	0	0
James Hill	0	0
John McKey	0	0
Philip Russell	0	0

Insider Trading

Name	Shares Traded	Price
EASTERN CAPITAL LTD	4,460,000	$0.00
KAY E GERALD	150,000	$0.76
MCKEY JOHN D JR	17,753	$0.99
MCKEY JOHN D JR	100	$1.04
MCKEY JOHN D JR	3,408	$0.99
MCKEY JOHN D JR	4,000	$0.99
MCKEY JOHN D JR	1,150	$1.08
MCKEY JOHN D JR	17,307	$1.10
MCKEY JOHN D JR	3,300	$1.08
MCKEY JOHN D JR	902	$1.09
MCKEY JOHN D JR	1,600	$1.10
MCKEY JOHN D JR	9,975	$1.10
KAY E GERALD	10,000	$0.86
KAY E GERALD	7,500	$0.88
KAY E GERALD	2,500	$0.85
KAY E GERALD	5,000	$0.73
KAY E GERALD	2,500	$0.83
KAY E GERALD	2,500	$0.82
KAY E GERALD	10,000	$0.70
KAY E GERALD	900	$0.72
MCKEY JOHN D JR	100,000	$0.65
DESANTIS CARL R	10,000	$3.00

» Full list on Insider Trading

People: Ibio Inc (IBIO.A)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: